Title:
COMBINATION THERAPY OF ACYLTHIOUREA COMPOUND AND ABIRATERONE
Document Type and Number:
WIPO Patent Application WO/2020/059744
Kind Code:
A1
Abstract:
Provided is a cancer combination therapy which exhibits an excellent anti-tumor effect and has less side effects by using an acylthiourea compound which is a selective inhibitor of c-Met or a pharmaceutically acceptable salt thereof. Also, provided is an anti-tumor agent containing a compound represented by formula (I) below or a pharmaceutically acceptable salt thereof, the anti-tumor agent being characterized by being administered in combination with abiraterone or a derivative thereof.
More Like This:
Inventors:
ISHIBASHI YUKO (JP)
Application Number:
PCT/JP2019/036530
Publication Date:
March 26, 2020
Filing Date:
September 18, 2019
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/47; A61K31/58; A61P13/08; A61P19/00; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| WO2009125597A1 | 2009-10-15 | |||
| WO2013100014A1 | 2013-07-04 | |||
| WO2015046484A1 | 2015-04-02 | |||
| WO2016208744A1 | 2016-12-29 | |||
| WO2016175305A1 | 2016-11-03 | |||
| WO2018151177A1 | 2018-08-23 | |||
| WO2014165779A1 | 2014-10-09 |
Foreign References:
| JP2016515628A | 2016-05-30 |
Other References:
FUJITA H. ET AL.: "The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile", MOL.CANCER THER., vol. 12, 2013, pages 2685 - 2696, XP055349054, DOI: 10.1158/1535-7163.MCT-13-0459
WATANABE K. ET AL.: "The MET/vascular endothelial growth factor receptor(VEGFR)-targeted tyrosine kinase inhibitor also attenuates FMS-dependent osteoclast differentiation and bone destruction induced by prostate cancer", J. BIOL. CHEM., vol. 291, 2016, pages 20891 - 20899, XP055694857
FUJITA H. ET AL.: "High potency VEGFRs/MET/FMS triple blockade by TAS-115 concomitantly suppresses tumor progression and bone destruction in tumor-induced bone disease model with lung carcinoma cells", PLOS ONE, 2016, vol. 11, pages e0164830, XP055694860
N. ENGL. J. MED., vol. 364, 2011, pages 1995 - 2005
N. ENGL. J. MED., vol. 368, 2013, pages 138 - 48
LANCET ONCOL., vol. 19, 2018, pages 194 - 206
H. FUJITA ET AL., PLOS ONE, vol. 11, no. 10, 2016, pages e0164830
N. MATSUBARA ET AL., ANNALS OF ONCOLOGY, vol. 28, no. 5, 1 September 2017 (2017-09-01)
See also references of EP 3854395A4
WATANABE K. ET AL.: "The MET/vascular endothelial growth factor receptor(VEGFR)-targeted tyrosine kinase inhibitor also attenuates FMS-dependent osteoclast differentiation and bone destruction induced by prostate cancer", J. BIOL. CHEM., vol. 291, 2016, pages 20891 - 20899, XP055694857
FUJITA H. ET AL.: "High potency VEGFRs/MET/FMS triple blockade by TAS-115 concomitantly suppresses tumor progression and bone destruction in tumor-induced bone disease model with lung carcinoma cells", PLOS ONE, 2016, vol. 11, pages e0164830, XP055694860
N. ENGL. J. MED., vol. 364, 2011, pages 1995 - 2005
N. ENGL. J. MED., vol. 368, 2013, pages 138 - 48
LANCET ONCOL., vol. 19, 2018, pages 194 - 206
H. FUJITA ET AL., PLOS ONE, vol. 11, no. 10, 2016, pages e0164830
N. MATSUBARA ET AL., ANNALS OF ONCOLOGY, vol. 28, no. 5, 1 September 2017 (2017-09-01)
See also references of EP 3854395A4
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: